The FDA announced regulatory actions Friday to support development of serotonin-2A agonists and related products, including psychedelic drugs. FDA begins push to study psychedelics for mental health disorders
The FDA announced regulatory actions Friday to support development of serotonin-2A agonists and related products, including psychedelic drugs. 
6 months ago
63
English (US) ·